Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP12 | P39900 | 17/20 | 1.00 |
| ▸ | MMP2 | P08253 | 15/20 | 1.00 |
| ▸ | MMP9 | P14780 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636847 | 0.86 | MMP1 (0.76) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL22959461 | 0.86 | MMP1 (1.00) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL22959440 | 0.86 | MMP1 (0.76) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL3761110 | 0.80 | MMP2 (0.67) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL7369379 | 0.78 | KMT2A (0.67) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL1255803 | 0.78 | MMP1 (0.69) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL27391742 | 0.77 | MMP2 (0.63) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL1170982 | 0.77 | MMP2 (0.65) | MMP1MMP12MMP2MMP9 | |
| SCHEMBL26630673 | 0.77 | MMP1 (0.64) | MMP1MMP12MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL27794217 | 0.75 | MMP2 (0.63) | MMP1MMP12MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2021026429-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357154-A1 | BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CHAT | MMP1 684/4885MMP12 1602/4885MMP2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.